243
Views
5
CrossRef citations to date
0
Altmetric
Articles

Data mining for detecting signals of adverse drug reaction of doxycycline using the Korea adverse event reporting system database

ORCID Icon, ORCID Icon & ORCID Icon
Pages 2192-2197 | Received 27 Apr 2021, Accepted 23 May 2021, Published online: 16 Jun 2021

References

  • Henehan M, Montuno M, De Benedetto A. Doxycycline as an anti-inflammatory agent: updates in dermatology. J Eur Acad Dermatol Venereol. 2017;31(11):1800–1808.
  • Colaizzi JL, Klink PR. pH-Partition behavior of tetracyclines. J Pharm Sci. 1969;58(10):1184–1189.
  • Atigari OV, Hogan C, Healy D. Doxycycline and suicidality. BMJ Case Rep. 2013;2013:pii:bcr2013200723.
  • Basaria S, Braga M, Moore WT. Doxycycline-induced hypoglycemia in a nondiabetic young man. South Med J. 2002;95(11):1353–1354.
  • Choi NK, Park BJ. [Adverse drug reaction surveillance system in Korea]. J Prev Med Public Health. 2007;40(4):278–284.
  • Soukavong M, Kim J, Park K, et al. Signal detection of adverse drug reaction of amoxicillin using the korea adverse event reporting system database. J Korean Med Sci. 2016;31(9):1355–1361.
  • Bate A, Lindquist M, Edwards IR, et al. A data mining approach for signal detection and analysis. Drug Saf. 2002;25(6):393–397.
  • Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10(6):483–486.
  • Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 2004;13(8):519–523.
  • Bate A, Lindquist M, Edwards IR, et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol. 1998;54(4):315–321.
  • Ståhl M, Lindquist M, Edwards IR, et al. Introducing triage logic as a new strategy for the detection of signals in the WHO Drug Monitoring Database. Pharmacoepidemiol Drug Saf. 2004;13(6):355–363.
  • Jinhyung K, Chungam C, Jung Mi O, et al. Use of Information Component (IC) and Relative Risk (RR) for signal detection of drug interactions of Clopidogrel: data-mining study using health insurance review & assessment service (HIRA) claims database. Korean J Clin Pharm. 2011;21(2):90–99.
  • Shih AR, Lauwers GY, Mattia A, et al. Vascular injury characterizes doxycycline-induced upper gastrointestinal tract mucosal injury. Am J Surg Pathol. 2017;41(3):374–381.
  • Kikendall JW. Pill esophagitis. J Clin Gastroenterol. 1999;28(4):298–305.
  • Holmes NE, Charles PGP. Safety and efficacy review of doxycycline. Clin Med Ther. 2009;1:CMT.S2035.
  • Vassileva SG, Mateev G, Parish LC. Antimicrobial photosensitive reactions. Arch Intern Med. 1998;158(18):1993–2000.
  • Hasan T, Kochevar IE, McAuliffe DJ, et al. Mechanism of tetracycline phototoxicity. J Invest Dermatol. 1984;83(3):179–183.
  • Piette J, Decuyper J, Van de Vorst A. DNA alterations photosensitized by tetracycline and some of its derivatives. J Invest Dermatol. 1986;86(6):653–658.
  • Böhm R, Proksch E, Schwarz T, et al. Drug hypersensitivity. Dtsch Arztebl Int. 2018;115(29–30):501–512.
  • Bhambri S, Kim G. Use of oral doxycycline for Community-Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) infections. J Clin Aesthet Dermatol. 2009;2(4):45–50.
  • Patel M, Bowe WP, Heughebaert C, et al. The development of antimicrobial resistance due to the antibiotic treatment of acne vulgaris: a review. J Drugs Dermatol. 2010;9(6):655–664.
  • Petrelli F, Ghidini M, Ghidini A, et al. Use of antibiotics and risk of cancer: a systematic review and meta-analysis of observational studies. Cancers. 2019;11(8):1174.
  • Velicer CM, Heckbert SR, Lampe JW, et al. Antibiotic use in relation to the risk of breast cancer. JAMA. 2004;291(7):827–835.
  • Li W-Q, Drucker AM, Cho E, et al. Tetracycline use and risk of incident skin cancer: a prospective study. Br J Cancer. 2018;118(2):294–298.
  • Nanda N, Dhawan DK, Bhatia A, et al. Doxycycline promotes carcinogenesis & metastasis via chronic inflammatory pathway: an in vivo approach. PLoS One. 2016;11(3):e0151539.
  • Administration USFaD. DORYX® (doxycycline hyclate) Delayed-Release Capsules, 75 mg and 100 mg. 2020; [cited 2020 Oct 10]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050582s031lbl.pdf.
  • Workowski KA, Bolan GA. Centers for disease C, prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015;64(RR-03):78–82.
  • Graham A, Hamoda H. Treatment of polycystic ovarian syndrome in primary care. Prescriber. 2016;27(11):36–45.
  • McDonnell R, Hart RJ. Pregnancy-related outcomes for women with polycystic ovary syndrome. Women’s Health. 2017;13(3):89–97.
  • Cohlan SQ, Bevelander G, Tiamsic T. Growth inhibition of prematures receiving tetracycline: a clinical and laboratory investigation of tetracycline-induced bone fluorescence. Am J Dis Child. 1963;105(5):453–461.
  • Eland IA, Belton KJ, van Grootheest AC, et al. Attitudinal survey of voluntary reporting of adverse drug reactions. Br J Clin Pharmacol. 1999;48(4):623–627.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.